Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Dova Pharmaceuticals Took Off in September

By John Bromels - Updated Oct 9, 2019 at 2:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

All it takes is one top drug.

What happened

Shares of drugmaker Dova Pharmaceuticals (DOVA) rose by 86.5% in September, according to data provided by S&P Global Market Intelligence.

This added to Dova's big gains in 2019, piggybacking on a June jump of 59.9%. Year to date, the company's shares have skyrocketed 271.2%. And it's all thanks to one drug.

An eyedropper drips clear liquid into a test tube.

Dova Pharmaceuticals' outperformance is due to the success of a single drug, Doptelet. Image source: Getty Images.

So what

The big winner for Dova has been Doptelet, a treatment for adults who don't have enough platelets in their blood. Platelets are the blood cells that cause clotting, so people who don't have enough -- a condition known as thrombocytopenia -- can be at risk of excessive bleeding due to injury or surgery.

Doptelet was already approved to treat thrombocytopenia in adult patients with chronic liver disease who were about to undergo surgery. As you can imagine, that's a very limited pool of potential patients. In June, however, the Food and Drug Administration gave additional approval to Doptelet for use in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. That caused Dova's stock to soar.

It also attracted the interest of drugmaker Swedish Orphan Biovitrum (SWTUY), also known as Sobi, which focuses on rare diseases with a major interest in hematology (blood disorders). Sobi agreed to acquire Dova for $27.50 a share, a 36% premium, to gain access to the company's platelet treatments and additional U.S. market exposure. The deal also offers Dova shareholders an additional "$1.50 per share upon approval of Doptelet for use in Chemotherapy-Induced Thrombocytopenia (CIT)" by the FDA.

Now what

If you're a Dova shareholder, congratulations -- this is about the best possible outcome one can get when purchasing shares of a small biotech company. Right now, the stock price is hovering around $28.20 per share, meaning the market is assigning about a 50-50 chance of getting that CIT approval from the FDA. But the difference between today's price and the full $29 per share is just 2.8%, so most Dova investors will probably just want to sell at the current price rather than wait around.

If you're not already a Dova shareholder, there's no real point to buying the stock now. Consider taking a look elsewhere in the sector.

John Bromels has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dova Pharmaceuticals, Inc. Stock Quote
Dova Pharmaceuticals, Inc.
DOVA
Swedish Orphan Biovitrum AB (publ) Stock Quote
Swedish Orphan Biovitrum AB (publ)
SWTUY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.